Skip to main navigation
Skip to search
Skip to main content
Aston Research Explorer Home
Help & FAQ
Home
Research units
Profiles
Research Outputs
Datasets
Student theses
Activities
Press/Media
Prizes
Equipment
Search by expertise, name or affiliation
Calcitonin gene-related peptide, adrenomedullin and flushing
Debbie L. Hay,
David R. Poyner
College of Health and Life Sciences
Aston Pharmacy School
Aston Research Centre for Health in Ageing
Aston University
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Calcitonin gene-related peptide, adrenomedullin and flushing'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Calcitonin Gene-related Peptide
100%
Adrenomedullin
100%
Postmenopausal Women
33%
Vasodilation
8%
Intermedin
8%
Hypothalamus
8%
Sweating
8%
Androgen Deprivation Therapy
8%
Thermoregulatory Center
8%
Peptide Concentration
8%
Facial Flushing
8%
Estrogen Replacement Therapy
8%
Hot Flushes
8%
Temporal Relations
8%
Biochemistry, Genetics and Molecular Biology
Calcitonin Gene-Related Peptide
100%
Adrenomedullin
100%
Postmenopause
27%
Calcitonin Blood Level
18%
Blood Plasma
9%
Calcitonin Gene-Related Peptide Receptor Antagonist
9%
Melanocyte-Stimulating Hormone
9%
Premenopause
9%
Sweating
9%
Vasodilatation
9%
Neuroscience
Calcitonin
100%
Adrenomedullin
100%
Blood Plasma
27%
Calcitonin Gene-Related Peptide Receptor Antagonist
9%
Melanocyte-Stimulating Hormone
9%
Androgen
9%
Hypothalamus
9%
Estrogen Replacement Therapy
9%
Vasodilation
9%
Nursing and Health Professions
Adrenomedullin
100%
Calcitonin Gene Related Peptide
100%
Calcitonin Blood Level
18%
Calcitonin Gene Related Peptide Receptor Antagonist
9%
Estrogen Therapy
9%
Intermedin
9%
Androgen Deprivation Therapy
9%
Hot Flush
9%
Pharmacology, Toxicology and Pharmaceutical Science
Calcitonin Gene Related Peptide
100%
Adrenomedullin
100%
Calcitonin Gene Related Peptide Receptor Antagonist
9%
Intermedin
9%
Replacement Therapy
9%
Hot Flush
9%
Androgen
9%